AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

Company Performance - AC Immune reported a quarterly loss of $0.25 per share, which was worse than the Zacks Consensus Estimate of$0.42, and compared to a loss of $0.22 per share a year ago, indicating a significant earnings surprise of -159.52$0.76 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 99.17%, and this is an increase from zero revenues a year ago [1] - Over the last four quarters, AC Immune has only surpassed consensus EPS estimates once [1] Stock Performance - AC Immune shares have declined approximately 30.2% since the beginning of the year, contrasting with the S&P 500's gain of 8.7% [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.22 on$1 million in revenues, and for the current fiscal year, it is -$0.20 on$99.11 million in revenues [4] - The estimate revisions trend for AC Immune is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [4] Industry Context - The Medical - Biomedical and Genetics industry, to which AC Immune belongs, is currently in the top 37% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [5] - Another company in the same industry, Agenus, is expected to report a quarterly loss of $1.33 per share, reflecting a year-over-year change of +66.8$64.73 million, up 155.8% from the year-ago quarter [5][6]